Introduction
Drug resistance is a nearly inevitable consequence of the deployment of antimicrobial drugs. This is an especially serious issue with regards to fungal pathogens as the conservation of their fundamental eukaryotic biology with mammalian host has limited development of fungus-specific therapies. The major class of antifungal drug used to treat fungal infections are the azole compounds that target a step in biosynthesis of the fungus-specific sterol ergosterol. Loss of the efficacy of the azole class of drugs is a negative indicator for the successful treatment of fungal infections. In the fungal pathogen Candida glabrata, azole resistance has been increasing for many years and reported to approach > 20% of C. glabrata-associated candidemias (Farmakiotis et al., 2015) . The facility of C. glabrata acquiring azole resistance is a likely contributing factor to this species becoming the second most commonly associated with candidemias (Cleveland et al., 2015) .
The importance of azole resistance as a complication to C. glabrata-associated candidemias has led to intensive study of the mechanisms underlying this clinical phenotype. Work from several labs found that the most frequent cause of azole resistance are mutations in the gene encoding a zinc cluster-containing transcription factor called Pdr1 (Vermitsky and Edlind, 2004; Tsai et al., 2006; Vermitsky et al., 2006) . These mutations are typically substitution mutants that produce a factor that exhibits high-level transcriptional activation of target genes (reviewed in [Morschhauser, 2010; ). One of the key Pdr1-regulated genes that is a central contributor to azole resistance is the CDR1 locus (reviewed in [Prasad and Goffeau, 2012] ). This gene encodes an ATP-binding cassette (ABC) transporter protein that is thought to act as a broad range ATP-dependent efflux pump limiting the accumulation of substrates, such as azole drugs (Wada et al., 2002) . Elevated expression of CDR1 is required for the observed drug resistance seen in gainof-function PDR1 strains (Sanglard et al., 1999) .
Pdr1 is a homologue of two closely related proteins from Saccharomyces cerevisiae called ScPdr1 and ScPdr3. Study of these factors in S. cerevisiae made clear predictions concerning the likely mechanism of action of C. glabrata Pdr1. For example, the DNA target site recognized by all these factors, referred to as the PDR Response Element (PDRE) was discovered in S. cerevisiae (Sc) and is conserved in C. glabrata (Katzmann et al., 1994; Vermitsky et al., 2006; Paul et al., 2011) . While ScPdr1 and Pdr3 as well as C. glabrata Pdr1 are the key regulators of azole resistance in both of these organisms, there are key differences between these transcriptional systems. Most obvious is that C. glabrata contains a single copy of PDR1 while S. cerevisiae expresses both ScPDR1 and ScPDR3. The C. glabrata protein was designated Pdr1 as it shares the highest degree of sequence similarity with ScPdr1 (Vermitsky and Edlind, 2004) . ScPDR3 is transcriptionally autoregulated while ScPDR1 is not (Delahodde et al., 1995) . Experiments in C. glabrata support the view that PDR1 is autoregulated in this yeast but key aspects of this model (Tsai et al., 2006; Paul et al., 2011) , such as the importance of the presumptive PDREs in the PDR1 promoter, remain unproven.
Here, we provide direct evidence supporting to idea that C. glabrata PDR1 represents a blend of the properties of ScPDR1 and ScPDR3. We confirm the necessary role of autoregulation in normal azole resistance and demonstrate that overproduction of the Pdr1 protein drives both elevated azole resistance and transcription of CDR1. Using an antibody directed against Pdr1, we demonstrate for the first time that although the Pdr1 polypeptide is synthesized at a higher level in GOF mutants, this altered transcription factor is also less stable than the wild-type protein. Finally, we discover that the central domain of Pdr1 is critical to restrain its activity under normal conditions. Removal of this central domain produces a Pdr1 derivative so transcriptionally active that it is not tolerated by the cell. These data provide new insights into the function of the crucial in vivo regulator of antifungal drug resistance in the human pathogen C. glabrata.
Results

Pdr1 regulation in an extrachromosomal setting
Development and thorough characterization of a lowcopy-number plasmid for C. glabrata (Zordan et al., 2013) prompted us to employ a plasmid-based system to examine Pdr1 function and regulation, similar to what has been done extensively in S. cerevisiae. We transformed wild-type and pdr1D cells with the empty vector plasmid and introduced this same plasmid carrying a wild-type copy of the PDR1 gene into the pdr1D strain. Appropriate transformants were grown to mid-log phase and tested for fluconazole resistance by spotting cells on media containing various concentrations of this drug. The low-copy-number plasmid carrying PDR1 fully complemented the fluconazole hypersensitivity of the pdr1D strain (Fig. 1A) .
To examine the regulation of Pdr1 expression from this plasmid context, we grew cells to mid-log phase in selective media. Incubation was allowed to proceed at this point with or without treating aliquots of these cultures with fluconazole. Protein extracts were prepared and analyzed by Western blotting for levels of Pdr1 and tubulin (Fig. 1B) . Although the expression level of plasmid-borne PDR1 was slightly lower than from its native location, this extragenic copy of PDR1 was still induced by fluconazole, albeit to a slightly lower level. These data are consistent with the DNA information present in this plasmid subclone being sufficient for normal drug induction of PDR1 transcription.
We took advantage of the plasmid-based copy of PDR1 to test the effect of high level overproduction of this factor on drug resistance and gene expression. To do this, we replaced the normal PDR1 promoter region with the cognate element from the highly expressed glycolytic gene TDH3 (glyceraldehye-3-phosphate dehydrogenase-encoding gene). Based on recent RNA-seq experiments (Linde et al., 2015) , we anticipated that the level of Pdr1 expression driven by the TDH3 promoter would far exceed that of the normal PDR1 promoter. Plasmid corresponding to the empty vector or the same clone containing the wild-type PDR1 gene or the TDH3-PDR1 fusion gene were transformed into a pdr1D strain. Transformants were grown in selective medium and then analyzed by western blotting for Pdr1 and tubulin (Fig. 1C ) or fluconazole resistance (Fig. 1D) .
As expected, the expression of Pdr1 was much higher when driven from the TDH3 promoter than its wild-type counterpart. Similarly, fluconazole resistance was also strongly increased in the presence of the TDH3-PDR1 fusion gene. To examine the effect of overproduced Pdr1 on CDR1 gene expression, we prepared a second low-copy-number plasmid containing a CDR1-lacZ fusion gene. This construct corresponded to a translational fusion between E. coli lacZ to the CDR1 ATG codon and 1000 bp of upstream promoter DNA. Using a pdr1D strain, we prepared double transformants containing either the empty vector or this same vector containing the wild-type PDR1 gene or the TDH3-PDR1 fusion gene along with the CDR1-lacZ reporter plasmid. Appropriate transformants were grown under selective conditions for both plasmids to mid-log phase and b-galactosidase activity determined as described previously (Katzmann et al., 1994) .
CDR1-lacZ expression was strongly elevated in the presence of the TDH3-PDR1 fusion gene (Fig. 1E ). Detectable expression of the reporter gene required the presence of PDR1 as lacZ levels dropped to background values when the empty vector plasmid was used in the pdr1D background. Two important findings emerged from this experiment. First, Pdr1 control of CDR1 expression requires only the promoter region and can occur in an episomal setting. Second, simply increasing the level of Pdr1 protein is sufficient to trigger an increased level of CDR1 transcription as previously suggested by the work of Tsai et al. (Tsai et al., 2006) . This finding is consistent with the idea that Pdr1 does not require an inducer (such as fluconazole) to act as a positive regulator of gene expression, at least when overproduced.
Dissection of the PDR1 autoregulatory circuit
Previous studies in C. glabrata (Tsai et al., 2006; Vermitsky et al., 2006; Paul et al., 2011) have supported the model that Pdr1 participated in a positive autoregulatory loop as seen for ScPdr3 (Delahodde et al., 1995; Hallstrom and Moye-Rowley, 2000b) . The requirement for this autoregulation in the physiological regulation of PDR1 expression remains unknown. Earlier work in β * Fig. 1 . Regulation of PDR1.
A. Fluconazole resistance assay of wildtype (MRY821) and pdr1D (MRY822) strains carrying an empty vector (Vector:pSK60) control or pSK60 containing a wild-type copy of the PDR1 gene (PDR1:pSK61). B. Western blot analysis of Pdr1 protein expression levels in the same transformants. Cells were grown in selective media overnight and then grown in YPD until mid-log phase, at which time an aliquot was challenged with 20 lg/ml fluconazole. Three OD 600 units of mid-log cultures were collected before (left panel) and 90 min after fluconazole treatment (right panel). Tubulin was used as a loading control. Absence of any plasmid is indicated by a minus sign (-). C. Western blot analysis of plasmid based Pdr1 protein expression levels driven by the wild-type PDR1 promoter (PDR1: pSK61) or the strong TDH3 promoter (TDH3: pSK99) in a pdr1D (MRY822) background. Tubulin was used as a loading control. The asterisk indicates a cross-reacting band unrelated to Pdr1. D. Fluconazole sensitivity assay of the same pdr1D (MRY822) transformants. 15,000 cells from mid-log SD -Leu cultures were spotted in 1:10 dilutions on YPD plates containing the indicated concentrations of fluconazole. E. CDR1 expression is elevated in response to increased Pdr1 levels. Double transformants were prepared in a pdr1D (MRY824) strain using a CDR1-lacZ plasmid and a low-copy-number vector (Vector: pSK60), or this same vector plasmid containing a wild-type copy of PDR1 (PDR1) or the TDH3-PDR1 fusion gene (TDH3-PDR1). Appropriate transformants were grown to mid-log phase and CDR1-dependent bgalactosidase levels determined using a standard method (Guarente, 1983) . These assays were performed on at least three independent biological replicates and the standard error was calculated.
S. cerevisiae demonstrated that the loss of a single PDRE could dramatically interfere with ScPdr3-regulated drug resistance (Zhang and Moye-Rowley, 2001 ). DNaseI footprinting experiments revealed that two binding sites for Pdr1 called Pleiotropic Drug Response Elements (PDREs) were located approximately 550 and 690 bp upstream of the ATG of the PDR1 gene in C. glabrata (Paul et al., 2011) . Mutations were prepared in each of these PDREs based on previously constructed substitution mutations that prevented PDRE binding of ScPdr1 and ScPdr3 (Katzmann et al., 1996) (Fig. 2A) . The upstream PDRE was designated PDRE 1 while the ATG proximal PDRE was designated PDRE 2. The mutant forms of each PDRE were introduced individually or together into a low-copynumber plasmid containing an otherwise wild-type copy of PDR1. An empty vector form of this plasmid or the four different versions of the PDREs were transformed into a pdr1D strain. Selected transformants were grown to midlog phase and then compared for their capacity to complement the fluconazole hypersensitivity of this strain and for expression levels of Pdr1 in the absence or presence of fluconazole in the medium by western blotting.
Loss of either PDRE alone had only a modest effect on fluconazole resistance (Fig. 2B ) but elimination of both PDREs prevented normal resistance from developing at either concentration of fluconazole tested. Western blotting in the absence of fluconazole indicated that Pdr1 levels were lowered to approximately 50% of the wildtype when either PDRE was removed and to 25% when both PDREs were mutated (Fig. 2C) . Interestingly, when these transformants were induced with fluconazole prior to western analysis, all these derivatives were A. Schematic representation of the location of the two pleiotropic drug response elements (PDREs) located in the PDR1 promoter. The numbering is relative to the PDR1 ATG codon with 11 corresponding to the adenine residue of this codon. Wild-type (wt) and loss-offunction mutant (m) sequences of PDRE1 and PDRE2 are indicated below the diagram. Mutated bases are shown in lower case letters and underscored in the wild-type. B. Fluconazole resistance assay of a pdr1D (MRY822) strain transformed with the low-copy-number vector plasmid pSK60 (Vector) or this same plasmid containing the wild-type PDR1 gene called pSK61 (wt). Mutant forms of the pSK61 were prepared that lacked either PDRE1, PDRE2 or both. These plasmids were designated pSK75 (mPDRE1), pSK79 (mPDRE2) and pSK78 (mPDRE1&2) respectively. All transformants were grown until mid-log phase in selective media and then plated in 1:10 dilutions onto fluconazolecontaining YPD plates. C. The same transformants were challenged with 20 lg/ml fluconazole for 90 min and then analyzed for Pdr1 and tubulin protein levels by western blot as above. D. Plasmids containing the indicated versions of the PDR1 gene or the empty vector were transformed into pdr1D cells along with a CDR1-lacZ reporter plasmid. Double transformants were assayed for b-galactosidase levels as before.
up-regulated by two-fold; even the mutant lacking both PDREs. This finding demonstrates that these PDREs in the PDR1 promoter are essential for normal regulation of this gene and represent the primary determinants of PDR1 transcription levels. These same plasmids containing PDR1 genes with different numbers of PDREs were then introduced into a pdr1D strain along with the CDR1-lacZ reporter gene. Selected double transformants were grown to mid-log phase and CDR1-dependent b-galactosidase activity measured (Fig. 2D) . Loss of the PDREs from the PDR1 promoter reduced expression of the downstream CDR1 target gene to very low levels, confirming the importance of these elements in maintenance of CDR1 transcription and associated azole resistance.
Structure-function analysis of Pdr1
Little direct analysis has been reported to define the functionally important regions of Pdr1. As described previously for ScPdr1/Pdr3 (reviewed in (Moye-Rowley, 2003) ), mutations that trigger a hyperactive phenotype of PDR1 are scattered across the C-terminus of the factor (Ferrari et al., 2009) . We previously expressed the amino-terminal 300 residues of Pdr1 that were sufficient to produce DNA-binding activity (Paul et al., 2011) . Based on sequence similarity with ScPdr1, we anticipated that the transcriptional activation domain of Pdr1 would be located in the extreme C-terminus between residues 968 and 1107 (Hallstrom and Moye-Rowley, 2000a) . The relative locations of these domains are indicated in Fig. 3A .
To provide a simple system to compare different mutant forms of PDR1 with their corresponding function, we used the plasmid-based system described earlier. Substitution mutant derivatives of Pdr1 were identified in clinical isolates using congenic strains that varied in their level of fluconazole resistance (Ferrari et al., 2009) . While each resistant mutant was closely related to its drug susceptible wild-type counterparts, there were multiple amino acid changes typically present in addition to the gain-of-function alteration and even more changes between corresponding wild-type isolates. We regenerated the gain-of-function alleles by site-directed mutagenesis in a single common wild-type gene in order to eliminate any confounding interactions from other amino acid alterations. These mutations were constructed in an otherwise wild-type PDR1 gene carried on a lowcopy-number plasmid and introduced into a pdr1D strain. Appropriate transformants were then tested for their ability to support fluconazole resistance (Fig. 3B ), steady-state protein level (Fig. 3C ) and analyzed for their effect on CDR1 expression (Fig. 3D) .
All of these gain-of-function alleles supported very high levels of fluconazole resistance and CDR1 expression. These data fully support earlier studies performed with a more complex genetic background that indicated these amino acid changes were likely responsible for the increased fluconazole resistance in the corresponding clinical isolate (Ferrari et al., 2009) .
Western blotting demonstrated that all of these hyperactive forms of Pdr1 were also expressed at a higher level than the wild-type protein (Fig. 3C ). Together, these findings establish that single amino acid substitution mutant forms of Pdr1 possess both elevated function and enhanced expression. The autoregulatory control of Pdr1 links these two changes since increased Pdr1 function will likely induce elevated protein levels. To separate these two features of Pdr1, we used the PDRE mutants to either reduce or block PDR1 autoregulation. We selected two of the gain-offunction forms to employ in this analysis: D1082G and P822L. PDRE 1 and 2 were individually removed from the gene encoding D1082G Pdr1 while mutant derivatives lacking both PDREs were constructed for the two hyperactive forms. These plasmids were transformed into a pdr1D strain and assayed for three different aspects of Pdr1 function: fluconazole resistance, steady-state protein level and expression of the CDR1 reporter gene.
Removal of individual PDREs had only minor effects on fluconazole resistance supported by the D1082G allele of PDR1 (Fig. 4A ). However, removal of both PDREs led to a clear reduction in fluconazole resistance that could be provided by either hyperactive form of Pdr1. Western blotting indicated that the elevated Pdr1 expression seen in the gain-of-function forms required both PDREs to be fully maintained (Fig. 4B ). This analysis indicates the relatively equal contribution of both PDREs to normal PDR1 promoter function.
These PDR1 plasmids were also co-transformed along with the CDR1-lacZ reporter plasmid to evaluate effects of these mutations on expression of Pdr1 target genes. In the case of the D1082G Pdr1, loss of either PDRE individually led to a two-or nearly 5-fold reduction in CDR1 expression (Fig. 4C ). It is important to note that both of these mutant promoters still supported increased Pdr1-dependent transcription as the wild-type PDR1 only drives 5 units/OD 600 of b-galactosidase activity under these conditions (e.g., see Fig. 1E ). Removal of both PDREs strongly reduced the function of both hyperactive alleles. These data help illustrate the fundamental role of the PDREs in establishing normal function of Pdr1 as well as the mutant phenotypes of gain-of-function alleles via autoregulation of transcription.
Hyperactive forms of Pdr1 have differential stability
Along with the experiments above that were addressed at control of Pdr1 protein levels of both the wild-type and gain-of-function forms, we wanted to directly assess the synthesis and degradation rate of these different versions of Pdr1. To accomplish this, we used a pulse-chase immunoprecipitation analysis employing our anti-Pdr1 antiserum. Transformants carrying low-copynumber plasmids expressing the wild-type Pdr1 or 4 different gain-of-function mutant forms were grown to early log phase, briefly labeled with 35 S-containing methionine and then a large excess of nonradioactive methionine was added. Aliquots were removed immediately after addition of the nonradioactive methionine (0 min) as well as 30 and 60 min later. Proteins were resolved on SDS-PAGE and radioactive polypeptides detected using a Typhoon imaging system. The pulse-labeling at time 0 gave a measure of the rate of Pdr1 protein synthesis and demonstrated that all gain-of-function polypeptides were produced at a higher rate than the wild-type factor. Three of the gain-offunction mutant proteins exhibited clear increases in their turnover compared to the wild-type factor ( Fig. 5A and B). The R376W, Y584C and P822L Pdr1 mutants were all degraded at a rate nearly twice as fast as the wild-type factor. The D1082G Pdr1 was also degraded faster than the wild-type protein but this effect was less pronounced. These data indicate that, along with the clear increase in the synthesis of Pdr1 in all gain-offunction mutants, the degradation of these mutant proteins is also enhanced.
An internal deletion mutant form of Pdr1 is a toxic hyperactive transcription factor
Introduction of the single amino substitution mutations into wild-type PDR1 confirmed that these changes gave rise to a hyperactive form of Pdr1. The sensitivity of the central domain of Pdr1 to mutation supported the view that this region of Pdr1 has a negative regulatory influence on function of the factor. To comprehensively probe this idea, we prepared an internal deletion derivative that lacked the amino acid sequence between residues 255-968 (Fig. 3A) . These endpoints were chosen based on comparison with a similar deletion made in the ScPdr1 transcription factor (Hallstrom and MoyeRowley, 2000a ). Loss of this region from ScPdr1 yielded a derivative that was hyperactive in a manner essentially identical to point mutant forms. The D255-968 PDR1 gene was cloned into a low-copy-number plasmid and introduced into a pdr1D strain along with the wild-type PDR1 gene as control (Fig. 6A) . We also constructed an amino-terminal TAP-tagged allele of both the wild-type and D255-968 forms of PDR1 to facilitate immunoblotting.
Our first experiments were directed towards comparing the function of wild-type and D255-968 PDR1 in pdr1D strains. We were surprised to find that the presence of the D255-968 PDR1 gene dramatically reduced the transformation efficiency of the resulting low-copy-number plasmid, although this effect was only seen in pdr1D background (Fig. 6A) . The transformation frequency of either the untagged or TAP-tagged version of D255-968 PDR1 was very similar to that of the empty vector in strains containing a chromosomal copy of wild-type PDR1. However, introduction of either of these plasmids into a pdr1D strain led to more than a 50-fold reduction in transformation efficiency. We compared the azole resistance of transformants with the untagged or TAP-tagged versions of wild-type or D255-968 PDR1 in cells containing chromosomal PDR1 (Fig. 6B) . Transformants expressing either the untagged or TAP-tagged versions of D255-968 PDR1 were found to have elevated drug resistance, consistent with the idea that CDR1-lacZ Fig. 4 . Autoregulation is essential for full activity of gain-of-function mutant alleles of PDR1. A. Wild-type or pdr1D cells were tested for their ability to grow on fluconazolecontaining YPD medium as described earlier. Transformants were prepared using an empty vector plasmid (Vector) or this same clone containing either wild-type or two different gain-of-function (GOF) forms of PDR1 (D1082G, left panel; P822L, right panel). The GOF versions of PDR1 were prepared with wild-type versions of the Pdr1 binding sites (PDRE), lacking PDRE1 (mPDRE1), lacking PDRE2 (mPDRE2) or lacking both PDREs (mPDRE1&2) as indicated. Selected transformants were grown to mid-log phase and placed on YPD medium containing the indicated concentrations of fluconazole. B. Transformants from above were grown to mid-log phase and whole cell protein extracts prepared. Equal volumes of protein were analyzed for levels Pdr1 and tubulin by western analysis as described earlier.
C. Double transformants were prepared from the indicated GOF forms of PDR1 with different PDRE present in their promoters along with the CDR1-lacZ reporter plasmid. In this case, presence of both wild-type PDREs is denoted as (wt). Expression of CDR1-dependent b-galactosidase was measured in mid-log cells as before. these internal deletion derivatives had elevated function compared to the corresponding wild-type PDR1 clones.
The dramatic reduction in transformation efficiency of pdr1D strains expressing only the D255-968 form of Pdr1 led us to construct a form of this mutant under control of the methionine-repressible MET3 promoter (Zordan et al., 2013) . The MET3 promoter region was used to replace the normal PDR1 promoter upstream of TAP-tagged forms of wild-type and D255-968 Pdr1. These plasmids transformed pdr1D cells at the same frequency as the empty vector (data not shown), consistent with the notion that the presence of the PDR1 promoter is required for the toxicity of the D255-968 PDR1 allele. Both the wild-type and D255-968 form of Pdr1 drove fluconazole resistance in a methioninesensitive manner as expected (Fig. 7A ). Interestingly, the resistance level supported by the TAP-D255-968 Pdr1 was higher than that of wild-type TAP-Pdr1. These data support the view that the D255-968 form of Pdr1 is more transcriptionally active than the wild-type protein.
To determine if the phenotypes we observed were the result of differential expression of the Pdr1 derivatives tested, we analyzed the steady-state levels of these proteins. The same transformants as above were grown to mid-log phase in the presence or absence of methionine as noted and then analyzed by western blotting using anti-Pdr1 antiserum. The MET3-regulated version of D255-968 Pdr1 (75 kDa) was strongly repressed by the addition of methionine as expected (Fig. 7B , compare lanes 2 and 3). Expression of this internal deletion mutant derivative of Pdr1 was readily detectable from the MET3 promoter in the absence of methionine in a pdr1D strain. Interestingly, the PDR1 promoter-driven D255-968 form of Pdr1 was present at levels very similar to those produced from the induced MET3 promoter (lane 4). Levels of the D255-968 Pdr1 were higher than those of the wild-type endogenous Pdr1. However, steady state levels of the TAP-Pdr1 protein (150 kDa) were higher than the D255-968 Pdr1 protein, irrespective of the use of either the native PDR1 or MET3 promoter (lane 6 and 7). Together, these data are consistent with the D255-968 Pdr1 possessing an increased ability to activate downstream gene expression compared to the wild-type factor. Next, we wanted to obtain a cell that contained the PDR1 promoter-driven D255-968 Pdr1 form as its primary version of this protein and used the conditional expression provided by the MET3 promoter to generate this strain. A pdr1D strain was cotransformed with the MET3-TAP-PDR1 expression plasmid and a clone containing the PDR1 promoter-driven TAP-D255-968 form of PDR1 or the corresponding empty vector. Cells were plated on media lacking methionine to ensure induced expression of the MET3 promoter. Transformants were recovered at the same frequency whether the two different TAP-PDR1 plasmids were present or if the cognate empty vector plasmids were used. This demonstrated that the lethality of the PDR1 promoter-driven D255-968 form of Pdr1 was being suppressed by the presence of the MET3-driven TAP-Pdr1. Transformants pregrown in medium lacking methionine were split into two aliquots. Methionine was added to one aliquot and growth continued until mid-log phase (6 hr). At this time, cells were harvested and analyzed by western blotting using anti-Pdr1 antibody.
Induction of the MET3 promoter allowed production of TAP-Pdr1 and the normal growth of these cells in the presence or absence of PDR1 promoter-driven D255-968 form of Pdr1 (Fig. 8A, lanes 4 and 6) . When the MET3 promoter was repressed, expression of the TAPtagged D255-968 form of Pdr1 was strongly induced compared to levels of this mutant protein in the presence of MET3-driven Pdr1 (compare lane 3 and 4) or MET3-driven D255-968 Pdr1 in pdr1D cells (Supporting Information Fig. S1, compare lanes 2 and 3) . The growth of these cells became very poor if incubation in the presence of methionine was allowed to continue more than 6 hr, consistent with the reappearance of the lethality driven by this internal deletion mutant form of Pdr1.
We used this acute depletion system to assess the activity of the TAP-tagged D255-968 form of Pdr1. The same double transformants and growth conditions as mentioned above were used. Total RNA was prepared after the 6 hour incubation in the presence or absence of methionine. Expression of the ABC transporterencoding CDR1 gene was then analyzed by qRT-PCR to determine the effect of the D255-968 form of Pdr1.
The striking increase in transactivation supported by the D255-968 form of Pdr1 could be seen when expression of the MET3-TAP-PDR1 gene was repressed by methionine addition (Fig. 8B) . Reducing the level of the wild-type TAP-Pdr1 protein with methionine repression of MET3 promoter increased CDR1 transcription level by more than 4-fold. Interestingly, the effect of the D255-968 Pdr1 could still be detected even when the MET3-TAP-PDR1 fusion gene was fully derepressed. Comparison of CDR1 mRNA levels produced in the absence of methionine between cells carrying both forms of Pdr1 expression plasmids and only the MET3-TAP-PDR1 clone demonstrated that the presence of the D255-968 Pdr1 still induced transcription by more than 4-fold even when A. Either a wild-type (PDR1) or pdr1D strain was transformed with a low-copy-number vector containing the indicated plasmids. Transformants were allowed to develop on minimal media at 308C for two days and then counted. Data are the results of two independent biological replicates and the standard deviation was calculated. B. Isogenic wild-type (PDR1) or pdr1D cells were grown to mid-log phase along with transformants of a strain containing a wild-type chromosomal copy of PDR1 (indicated by the bar labeled PDR1) and placed on rich YPD media either lacking or containing the indicated concentrations of fluconazole. Plates were allowed to develop at 308C and then photographed.
wild-type TAP-Pdr1 production was fully induced. Together, these data support the hypothesis that loss of the central domain of Pdr1 produced a hyperactive transcription factor that accumulates to toxic levels when produced if its normal autoregulatory circuit is intact.
We also examined mRNA levels for PDR1 and D255-968 PDR1 derivative using primers that were specific for each of these forms of PDR1. As expected, addition of methionine led to a strong repression of TAP-PDR1 transcription driven by the MET3 promoter (Fig. 9A) . Transcription of MET3-TAP-PDR1 in the absence of methionine was similar, irrespective of the presence of the PDR1-TAP-D255-968 PDR1 fusion gene. Expression of TAP-D255-968 PDR1 was elevated by approximately 3-fold when methionine was added to repress transcription of MET3-TAP-PDR1 (Fig. 9B) . These data confirm that the changes in protein levels we observed by western blot analysis above are primarily caused by similar effects on gene transcription.
Role of Med15A (Gal11A) in D255-968 PDR1 toxicity
Previous work has established that transcriptional activation via Pdr1 required the presence of the transcriptional Mediator complex subunit Gal11A (Thakur et al., 2008) . The standard nomenclature for Mediator subunits uses Med15 to refer to Gal11-like proteins and we will use this standard nomenclature here. Although C. glabrata contains two related Med15 proteins, Med15A and Med15B, Med15A has been demonstrated to be the major if not sole contributor to Pdr1 transactivation (Thakur et al., 2008) . To determine if Med15A was important in the unexpected toxicity of the D255-968 form of Pdr1, we prepared isogenic wild-type and pdr1D strains in which the chromosomal copy of MED15A was deleted (namely strains med15D and med15D pdr1D). These two strains, along with a pdr1D strain, were transformed with an empty vector plasmid or this same vector expressing either TAP-PDR1 or TAP-D255-968 PDR1 from the PDR1 promoter. 
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Vector Genotype Δpdr1 Δpdr1
TAP-Pdr1
TAP-Δ255-968 Pdr1
MET3-TAP-PDR1 PDR1-TAP-PDR1
MET3-TAP-Δ255-968-PDR1
PDR1-TAP-Δ255-968-PDR1
Met A. A. The pdr1D strain was transformed with a low-copy-number vector containing the MET3 promoter-driven TAP-PDR1 or the internal deletion mutant TAP-D255-968 PDR1. Transformants were grown to mid-log phase in minimal medium without methionine and aliquots of cells were placed on minimal medium containing or lacking additional methionine to repress the MET3 promoter. Fluconazole was also present where indicated at 80 lg/ml. Plates were incubated at 308C and then photographed. B. The low-copy-number vector plasmid (pCU) containing only the MET3 promoter (Vector) or the same plasmid with MET3 controlling transcription of the wild-type TAP-PDR1 or the TAP-D255-968 form of PDR1 was transformed into a pdr1D strain. Cells were grown to midlog phase either in the presence (1) or the absence (-) of methionine in the medium, protein extracts prepared and analyzed by western blotting using antiPdr1 or anti-tubulin antibodies. The pdr1D strain transformed with the lowcopy-number plasmid containing the wildtype TAP-PDR1 gene driven from PDR1 promoter and strain with chromosomal PDR1 copy transformed with TAP-D255-968 PDR1 driven by the PDR1 promoter were also included as controls for plasmid-based expression of this gene. Migration of the different forms of Pdr1 are indicated by arrows. Molecular weight standards are listed on the right hand side in kilodaltons.
As discussed above, the presence of the TAP-D255-968 PDR1 clone produced a striking decrease in transformation efficiency in pdr1D cells compared to all other plasmids. Interestingly, this decrease could be fully rescued with deletion of the MED15A gene from the pdr1D background (Fig. 10A) . Next, transformants carrying the three different plasmids in each of the three different genetic backgrounds were grown to mid-log phase and then analyzed for their level of fluconazole resistance (Fig. 10B) as well as the expression of Pdr1 using anti-Pdr1 antibody (Fig. 10C) .
As found before, loss of either PDR1 or MED15A caused fluconazole sensitivity (Thakur et al., 2008) (Fig. 10B) . Reintroduction of the TAP-PDR1-expressing plasmid restored normal fluconazole resistance to a pdr1D strain but was unable to significantly increase drug resistance in a med15A strains even in the presence of a second copy of PDR1 at its normal chromosomal location. However, introduction of the TAP-D255-968 PDR1 plasmid into either the med15AD or the med15AD pdr1D strain elevated the level of fluconazole resistance, but to different extents. The presence of the TAP-D255-968 PDR1 allele in the med15AD pdr1D strain produced the highest level of fluconazole resistance as this transformant grew well at 40 lg/ml fluconazole. This same plasmid in the med15AD background (containing a chromosomal copy of PDR1) still elevated fluconazole resistance but was unable to support growth at the higher fluconazole concentration. 
PDR1-TAP-Δ255-968 PDR1
MET3-TAP-PDR1
PDR1-TAP-Δ255-968 PDR1
MET3-TAP-PDR1
& Fig. 9 . Levels of D255-968 PDR1 mRNA are induced upon depletion of wild type PDR1. A. Levels of PDR1 mRNA were analyzed by qRT-PCR employing primers that anneal to the region of central inhibitory domain of PDR1, thus detecting transcription of only wild-type PDR1. Levels of mRNA were normalized to the MET3-TAP-PDR1 and pCL cotransformant grown in the presence of methionine (1). B. Levels of the TAP-D255-968 PDR1 mRNA in the co-transformant pdr1D strain containing MET3-TAP-PDR1 and TAP-D255-968 PDR1 were detected using primers specific for internal deletion form of PDR1. The fold change in the expression of TAP-D255-968 PDR1 of the strain grown in the presence of methionine (1) was determined relative to the same strain grown in the medium without methionine (-). The experiment was performed in two technical replicates and two independent biological replicates. The standard deviation was also calculated. B.
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Fig. 8. D255-968 PDR1 is a hyperactive, gain-of-function mutant.
A. The pdr1D strain was used to prepare double transformants in the following combinations: empty pCU plasmid was cotransformed with empty pCL plasmid; or a plasmid containing MET3-driven TAP-PDR1 was co-transformed with the empty pCL plasmid or a plasmid containing TAP-D255-968 PDR1 under native PDR1 promoter control. Transformants were pregrown in media lacking methionine and then shifted into the same media either containing (1) or lacking (-) methionine. After 6 h at 308C (mid-log phase), whole cell protein extracts were prepared and analyzed by western blotting using anti-Pdr1 or anti-tubulin antibodies. B. The same cells from panel A were also processed for total RNA. Data from the qRT-PCR were analyzed using a standard method of quantification (DDCt) and the fold change in the expression of CDR1 was determined relative to a reference pdr1D strain cotransformed with empty pCU and pCL plasmids. The experiment was performed in two technical replicates and two independent biological replicates with the standard deviation calculated.
Western blot data revealed that the expression of the D255-968 form of Pdr1 was highest in the med15AD pdr1D strain (Fig. 10C, lane 4) . Loss of the Med15A subunit of Mediator allowed pdr1D cells to maintain plasmid containing the hyperactive D255-968 PDR1 allele as its only form of Pdr1 and still effectively drive azole resistance. On the other hand, the loss of Med15A (in the presence of wild-type PDR1) produced the lowest levels of D255-968 Pdr1 (Fig. 10C, lane 5) . By comparison, in wild-type cells of SPG96 strain the expressed levels of D255-968 Pdr1 were similar to those seen in the med15AD pdr1D strain (Fig. 10C , compare lane 4 land 6). Together, these data support the view that Med15A is an important feature of target gene activation by Pdr1, but other Mediator subunits still drive significant downstream gene transcription.
Discussion
A molecular understanding of the regulation of Pdr1 is of critical importance if interventions are to be developed to reverse the frequent azole resistance in C. glabrata caused by hypermorphic forms of this protein. The data reported here provide support for the idea that Pdr1 represents a blend of the properties of ScPdr1 and ScPdr3. Pdr1 shares the highest sequence similarity with ScPdr1 and possesses a similar central negative regulatory domain. Pdr1 also shares autoregulation and mitochondrial control (Tsai et al., 2006; Vermitsky et al., 2006) with ScPdr3 (Hallstrom and Moye-Rowley, 2000b) . Even though S. cerevisiae and C. glabrata share a common ancestor prior to their respective genome duplications, S. cerevisiae appears to have split (Gal11A) is required for the toxicity of the D255-968 form of Pdr1. A. Isogenic pdr1D, med15AD and med15AD pdr1D cells were transformed with either an empty vector plasmid or the same clone expressing the TAP-D255-968 PDR1. Transformants were allowed to develop on minimal media at 308C for two days and then counted. Data are the results of two biological replicates. B. An empty vector plasmid or this same backbone plasmid expressing either TAP-PDR1 or TAP-D255-968-PDR1 were introduced into the indicated strains. Transformants were grown to mid-log phase and then tested for fluconazole resistance by spotting serial dilutions on minimal medium lacking uracil (-ura) or YPD medium containing the indicated concentrations of fluconazole. Plates were incubated at 308C and photographed after 2 days. C. Plasmids corresponding to either a low-copy-number vector or this same plasmid expressing TAP-D255-968 PDR1 were introduced into isogenic wild-type, med15AD or med15AD pdr1D strains. Transformants were grown to mid-log phase and analyzed by western blotting using anti-Pdr1 antibody as described previously and anti-a-tubulin antibody to ensure equal loading. Fold change in protein levels of TAP-D255-968 PDR1 among different genetic backgrounds was compared by quantification of the signal intensity. Migrations of the different protein species are indicated on the left-hand side of the figures. Molecular mass standards are shown on the right-hand side in kD.
its zinc cluster-containing Pdr factor functions between two homologues while C. glabrata retained all of these in its single PDR1 gene. This retention of a single gene with all functions is not always the case for C. glabrata as S. cerevisiae has a single copy of the transcriptional Mediator component MED15 while C. glabrata contains two (Thakur et al., 2008) .
Our work extends the earlier studies of Ferrari et al. (Ferrari et al., 2009 ) by analyzing PDR1 GOF mutants in a classically isogenic manner. Introducing these clinically derived GOF mutations back into a single wild-type PDR1 gene allows us to accurately compare the relative strengths and differential functional properties of these mutants for the first time. Our data argue that the effects of each mutation may not be the same as the D1082G allele of PDR1 led to an insignificant effect on protein turnover while all the other GOF alleles reduced the t 1/2 by at least 50% (Fig. 5) . Future work will be directed towards clarifying the mechanisms of each GOF allele in terms of the effect on Pdr1 function.
A striking result reported here is the toxic nature of an internal deletion derivative of Pdr1. This mutation was generated based on our previous work showing that a similar mutant form of ScPdr1 behaved as a strong transcriptional activator (Hallstrom and Moye-Rowley, 2000a) . Loss of this cognate region from Pdr1 produced a transactivator protein that could not be tolerated as the sole source of Pdr1 in cells. The physiological importance of autoregulation of the PDR1 gene is illustrated by this lethality being reversed if the same deletion mutant is produced from the MET3 promoter. We interpret this loss of lethality as a consequence of eliminating autogenous control by Pdr1. This also suggests an explanation for why a similar mutant form of ScPdr1 is tolerated in S. cerevisiae as ScPDR1 is not subject to autoregulation (Delahodde et al., 1995) . Our findings in C. glabrata suggest that the hyperactive nature of the D255-968 Pdr1 protein coupled with the autoregulation supported by the normal PDR1 promoter cause high level production of this strong transactivator and may lead to sequestration of some key general transcription factor (squelching) (Gill and Ptashne, 1988) . It remains possible that specific overexpression of some normal Pdr1 target gene (in addition to PDR1 itself) is the cause of this toxicity. Our finding that this mutant form of Pdr1 is lethal suggests that deregulation of Pdr1 might have potential as a means to inhibit growth of C. glabrata.
The data reported here also illustrate a key difference between the gain-of-function point mutant forms of Pdr1 compared to the D255-968 Pdr1 version. Although the gain-of-function forms of Pdr1 still support high level expression of target genes like CDR1, these substitution mutants must retain some type of regulation that prevents them from causing the lethality seen in the presence of the D255-968 Pdr1 derivative. These data further illustrate the crucial role of the center domain of Pdr1 in control of its transcriptional activity in vivo. We hypothesize that other proteins act via this central domain to negatively regulate Pdr1 activity and that loss of certain amino acids (gain-of-function forms) or removal of the central domain (D255-968 Pdr1) cause partial or complete loss of negative regulation. Identification of these other proteins is a key goal for future research.
Analysis of the PDR1 promoter confirms the predicted important roles of the PDREs present in this DNA region. Mutagenesis of each PDRE uncovered two important facets of the control of expression of this gene. First, we confirm that autoregulation is a critical feature of the transcriptional regulation of PDR1 through these PDREs. Earlier experiments established that a PDR1-luciferase fusion required the presence of the endogenous PDR1 gene to be properly induced in q 0 cells lacking the mitochondrial genome (Paul et al., 2011) . Here, we provide the first demonstration that both PDREs are required for wild-type transcriptional autoregulation of PDR1. Second, the presence of a single PDRE still maintains the ability to produce wild-type fluconazole resistance and drug-induced expression of Pdr1 ( Fig. 2B and C) . The structure of the PDR1 promoter is also very different from that of the similarly autoregulated ScPDR3 promoter (Delahodde et al., 1995; Zhang and Moye-Rowley, 2001 ). Although both promoters contain two PDREs, their spacing and relative location from the ATG codon are dissimilar. The PDR1 promoter has approximately 136 bp between its two PDREs with the most ATG-proximal positioned 550 bp upstream. This is in contrast to ScPDR3 that has only 25 bp between its PDREs with its ATG-proximal at 183 bp upstream. Interestingly, ScPDR1 and CgPDR1 share a similar upstream chromosomal neighbor (ERG4 in both cases) but there are two important differences between these homologues. As mentioned above, the first difference is the lack of autoregulation in ScPDR1. Additionally, the spacing between the ScERG4 and ScPDR1 genes in S. cerevisiae is only 555bp while in Candida glabrata the two genes are separated by 3500 bp. These very different promoter structures are consistent with the more complex transcriptional control of CgPDR1 requiring additional sequence information.
Along with this analysis of cis-acting signals controlling PDR1 autoregulation, we have examined the contribution of Med15A to control of this gene. Importantly, we discovered that loss of Med15A allowed maintenance of the hyperactive D255-968 PDR1 allele as the sole source of Pdr1 in cells. Importantly, even in the absence of Med15A, the D255-968 form of Pdr1 can still elevate fluconazole resistance to a level above that of wild-type cells (Fig. 10B) . We interpret this as evidence that the D255-968 Pdr1 derivative can activate downstream gene transcription in both Med15A-dependent and independent manners. An important goal going forward will be to determine the basis of this additional route of Pdr1 target gene induction. Previously, we have shown that ScPdr3 can activate its target gene suites via engagement with either Med15-or Med12-dependent mechanisms (Shahi et al., 2010) .
Availability of our Pdr1-specific antiserum has allowed the levels of Pdr1 produced in the drug hyper-resistant strains to be assayed for the first time. Previous studies (Ferrari et al., 2009) have demonstrated that these mutant forms of Pdr1 exhibit increased mRNA production and here we establish that this also leads to elevated protein production. Western blotting also confirmed that Pdr1 protein levels were induced similarly to PDR1 transcript after challenge with fluconazole (Vermitsky et al., 2006) . This induction was not seen in any of the hyperactive mutants, likely due to their preexisting high levels due to autoregulation. A feature shared by the hyperactive mutants that was revealed by measurement of the protein turnover was their relative instability compared to the wild-type protein. These hyperactive mutants still exhibit elevated steady-state levels, even with their relatively higher turnover rates, consistent with an even larger increase in their synthesis rate. More detailed analyses are required to determine if the wildtype protein is less stable when exposed to fluconazole. Enhanced degradation of activated transcription factors provides for more rapid cessation of an induced response and has been seen for other positive regulatory factors (reviewed in [Muratani and Tansey, 2003] ).
Overproduction of wild-type Pdr1 using a strong glycolytic promoter does elevate downstream gene expression but to only 10% that of a typical gain-of-function mutant protein. This finding illustrates the fundamental difference in intrinsic activity between mutant and wild-type forms of Pdr1. Given that the TDH3-PDR1 gene fusion produces roughly 5X more protein than the gain-of-function forms of Pdr1, the specific activity of the overproduced wild-type activator protein is as much as 50-fold reduced compared to these hyperactive mutant regulators. Preliminary experiments indicated that the overproduced wild-type protein, like the GOF Pdr1, was not induced by exposure to fluconazole (data not shown). We interpret these data to indicate that high level production of the wild-type Pdr1 is able to overcome some negative regulatory input that would otherwise restrain this protein in a low activity form. An important goal of future work is to identify the nature of the negative regulatory signal as this is likely to be key feature of control of Pdr1 transcriptional activation and azole resistance.
Experimental procedures
Growth conditions and strains
Liquid cultures were grown at 378C unless stated otherwise. For drug treatments and non-selective growth, YPD (yeast extract 1%, peptone 2%, dextrose 2%) medium was used. For selective growth of C. glabrata strains transformed with plasmids, minimal SD (yeast nitrogen base with ammonium sulfate 0.67%, dextrose 2%) media supplemented with amino acids individually or as a complete supplement mixture (CSM) lacking either leucine, uracil, both at the same time or histidine only were used. Liquid cultures were grown at 308C in experiments that included regulation of the gene expression by MET3 promoter. To induce the expression of genes from the MET3 promoter, minimal selective SD medium lacking methionine was used for the cell growth. To repress the expression of genes from the MET3 promoter, the same medium including methionine to a final concentration of 2 mM was used. Cells grown to mid-log phase (OD 600 5 1) were used for subsequent experiments.
All strains used in this study are listed in Table 1 . To generate a ura3 auxotrophic derivative of KK2001, a ura3D(-85 1932 ::Tn903 NeoR cassette was amplified from the 40F1 strain (Srikantha et al., 2005) and integrated into KK2001 genomic DNA by transforming a PCR fragment followed by G418 (500 lg/ml RPI # G64000) selection. This ura3 mutant strain was designated SPG96. A pdr1D deletion in the SPG96 background was generated by transforming a This study pdr1D::natMX cassette amplified from MRY822 followed by 50 lg/ml Nourseothricin (cloNAT Jena Bioscience cat# AB102-L) selection and the strain was designated SKY107.
To generate a med15AD deletion in the SPG96 and SKY107 background, the med15AD:: HIS3MX6 cassette was prepared by Gibson assembly cloning into the pUC19 vector. The HIS3MX6 marker was amplified from plasmid pFA6a-HIS3MX6 (Addgene #41596). The marker was flanked by 1 kb of MED15A promoter and terminator sequence to enable homologous integration of the cassette into MED15A locus. MED15A promoter and terminator PCR products were amplified from genomic DNA of the strain SPG96. The pUC19 vector containing the cloned cassette was linearized by restriction enzyme SbfI (NEB #R3642S) and the cassette was transformed into SPG96 and SKY107 strains followed by selection on medium lacking histidine. The homologous integration of the cassette into the MED15A locus was confirmed by diagnostic PCRs. The med15AD pdr1D strain was designated as LSY2 and the med15AD strain as LSY3.
Plasmids
All plasmids used in this study are listed in Table 2 . For this study plasmid cloning was done using Gibson Assembly cloning kit (NEB #E5510S) unless otherwise specified. Primer design and reaction condition were performed according to manufacturer's recommendations. PDR1 expression constructs were generated in the low-copynumber vectors (pSK60) containing a C. glabrata CEN/ARS replication origin. To generate pSK60, the URA3 marker in the pCU vector (Zordan et al., 2013) was replaced with S. cerevisiae LEU2 gene amplified from pRS315. To generate the pSK61 construct, the PDR1 coding sequence with corresponding 847bp of promoter and 227bp terminator regions was amplified from MRY821 genomic DNA and cloned into the pSK60 vector. For the PDR1 overexpression construct, the strong promoter from the TDH3 gene encoding glyceraldehyde-3-phosphate dehydrogenasewas amplified from MRY821 genomic DNA and cloned into pSK61 replacing the PDR1 promoter. Point mutations in the PDR1 coding sequence and promoter region were introduced using PCR-based site directed mutagenesis (Zheng et al., 2004) of pSK61. In each case, a restriction site was either introduced or removed to facilitate detection of a given mutation. As a result of this strategy, all GOF PDR1 mutations were verified with restriction enzyme digest (pSK74 (Y584C) PstI; pSK68 -(P822L) NsiI; pSK70 -(D1082G) EcoRI; pSK75 -(mPDRE1) AsiSI; pSK79 -(mPDRE2) AscI; pSK78 -(mPDRE1&2) AsiSI and AscI sites introduced and pSK71 -(R376W) BsmAI site destroyed) and DNA sequencing. Mutant forms of the PDR1 promoter were sub-cloned into the SapI/PacI site of PDR1(D1082G):pSK70 and PDR1(P822L):pSK68 generating pSK86, pSK90, pSK91 and pSK87.
The lacZ reporter vector plasmid (pSK80) is a derivative of pSEYC102 (Emr et al., 1986) . A C. glabrata CEN/ARS was amplified from pSK60 and introduced into pSEYC102 replacing the S. cerevisiae CEN/ARS. The CDR1 promoter and ATG codon was amplified from MRY821 genomic DNA and placed in front of an E. coli lacZ reporter in the pSK80 clone generating pAK1. Plasmid-dependent b-galactosidase assays were conducted using a standard method (Guarente, 1983) .
To generate the pLS1 plasmid that contained the tandem affinity purification (TAP)-tagged allele of PDR1, the coding sequence of the TAP-tag was amplified from the genomic DNA of the C. glabrata Y733 strain and cloned into the URA3-marked plasmid pSP76 upstream of PDR1 ATG codon to give the N-terminally TAP-tagged PDR1 coding sequence under control of the native PDR1 promoter and terminator. To prepare the pLS2 plasmid, the same strategy was used to clone the TAP-tag into the URA3-marked plasmid pSK84 to obtain N-terminally TAPtagged D255-968 PDR1 coding sequence under control of its native promoter and terminator. To obtain a LEU2-marked version of this plasmid (pLS3), the URA3 marker was replaced with the ScLEU2 marker as mentioned previously. To generate TAP-PDR1 driven from the MET3 promoter, N-terminally TAP-tagged PDR1 was amplified from the pLS1 plasmid and cloned downstream from the MET3 promoter in the URA3-marked pCU plasmid (pLS4). The same strategy was used to prepare the URA3-marked plasmid containing N-terminally TAP-tagged D255-968 PDR1 under control of MET3 promoter (pLS5).
Transformation
Candida glabrata cell transformation was performed using a lithium acetate method (Gietz and Schiestl, 1995) . Cells 
Drug treatment
Mid-log phase cells (OD 600 5 1) were spotted in 1:10 serial dilutions on fluconazole containing YPD or minimal SD plates. For western blot analysis, mid-log cells were treated with 20 lg/ml fluconazole (LKT Laboratories, Inc. #F4682).
Real-time PCR
Five OD 600 units of mid-log phase cells were harvested per sample. Total RNA was isolated according to the instructions in the RNeasy mini kit (Qiagen) including the oncolumn DNAse digestion step. Synthesis of cDNA was performed using iScript cDNA Synthesis Kit (Bio-Rad) with 500 ng of RNA as a template. Quantitative real-time PCR (qRT-PCR) was accomplished using the iTaq Universal SYBR Green Supermix (Bio-Rad) in MyIQ 2 Two Color Real-Time PCR Detection System (Bio-Rad). Melting curve was analyzed with each run to evaluate nonspecific amplification. The threshold cycle (C t ) values were determined for each gene and the average C t value for each sample was calculated from the triplicate. The average C t value of CgTEF1 gene was used for normalization of variable cDNA levels, and induction factors were determined for each gene and condition. The comparative 2 -DDCt method was used to calculate the fold change of the gene of interest between samples. (Livak and Schmittgen, 2001) . The experiment was repeated in two technical and biological replicates. The same culture of cells that was used for qRT-PCR was used also for western blot analysis. The transcript levels of tested CDR1 and PDR1 forms were analyzed from the same culture.
Western blot analysis
Cells were grown to mid-log phase in rich YPD or minimal SD media for plasmid selection. Three OD 600 units of culture were harvested per sample. Protein extracts were prepared as previously described (Shahi et al., 2010) . Protein pellets were resuspended in 50 ml/OD 600 unit of urea sample buffer (8 M urea, 1% 2-mercaptoethanol, 40 mM Tris-HCl pH 8.0, 5% SDS, bromophenol blue). The resuspended proteins were boiled at 908C for 10 min and an aliquot was resolved on 8% SDS-PAGE or precast ExpressPlus 4-15% gradient gel (GenScript #M41212) following the manufacturer's SDS-PAGE protocol. The proteins were transferred to a nitrocellulose membrane, blocked with 5% nonfat dry milk, and then probed with antiPdr1 antibody diluted 1:2,000-6,000. All membranes were probed for tubulin as loading control with 12G10 anti-alpha-tubulin monoclonal antibody (Developmental Studies Hybridoma Bank at the University of Iowa) for 30 min at room temperature. The membrane was probed with secondary Li-Cor antibodies IRD dye 680RD goat anti-rabbit (# 926-68071) or IRD dye 680LT goat antirabbit (# 926-68021) and IRD dye 800CW goat anti-mouse (# 926-32210) diluted 1:15,000-20,000. Western blot signal was detected using a Li-Cor Odyssey infrared imaging system, application software version 3.0 and quantified using Image Studio Lite software (Li-Cor).
Pulse chase analysis
Cells were grown for 12 h at 378C in selective minimal media. Saturated cells were diluted to OD 600 of 0.1 and grown at 378C for two doubling times. 10 OD 600 units of cells were harvested per time point and incubated in selective minimal media without methionine for 15 min at 378C with shaking. Expre 35 S 35 S Protein Labeling Mix (PerkinElmer #NEG072014MC) was added to 15 lCi/OD 600 unit cells into the media and suspension was incubated for 12 min at 378C with shaking. Termination of the labeling reaction was achieved by adding excess of cold methionine and cysteine (5 mg/ml each) diluted 100x in the media. Cell aliquot corresponding to the time point "0" was removed from the medium immediately after cold methionine and cysteine were added and placed on ice into the tube containing sodium azide to the final concentration of 20 mM. Aliquots from three time points (0, 30 and 60 min) were collected. Cells were harvested, washed with of 10 mM sodium azide and resuspended in the RIPA lysis buffer (25 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% sodium deoxycholate, 1% Nonidet, 0.1% SDS) complemented with 1% SDS, 10 mM EDTA, 1 mM PMSF and 1x Complete protease inhibitor. After glass beads (0.5 mm) were added to the surface, lysis was performed by shaking the samples for 10 min at maximum speed. Equal volume of the RIPA buffer (as above) without SDS was added to the samples and the insoluble material was pelleted by centrifugation at top speed. After the polyclonal Pdr1 antibody was added to the supernatant in 1:100 dilution, the cell lysate was incubated overnight at 208C by rotation. Immunoprecipitation was performed using 50 ll of Protein A/G PLUS-Agarose Immunoprecipitation Reagent (Santa Cruz Biotechnology). Agarose beads were first equilibrated overnight at 48C with the RIPA buffer. After adding the cell lysate with Pdr1 antibody to the beads, the mixture was incubated for 3 h at 208C by rotation. Immunoprecipitates were collected by centrifugation and the pellet was washed four times with the RIPA buffer, each time repeating the centrifugation step. Pellets were incubated in 25 ll of urea sample buffer (8 M urea, 40 mM Tris pH 8.0, 5% SDS, 5% 2-mercapthoethanol, 10% glycerol, bromophenol blue) for 30 min at 378C and 20 ll of the eluate were loaded onto the 8% SDS-PAGE gel and separated. The gel was then incubated in fixing solution (40% methanol, 5% acetic acid) on a shaker for 20 min at room temperature, followed by incubation in 1 M sodium salicylate under the same conditions. The gel was dried for 35 min at 808C and the signal detected by Typhoon phosphoimager. Protein densitometry was quantified by ImageJ 1.5 (Schneider, C. A. et al. [2012] , Nature methods). Half lives of wild type and mutant forms of Pdr1 were calculated based on the equation t 1/2 5 ln(2)/k where k is the rate constant. Protein half lives were calculated from two biologically independent experiments.
